Eli Lilly said on Tuesday it had sued two mass compounders for selling unapproved products that contain tirzepatide, the main ...

Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 ...

Eli Lilly (NYSE:LLY) on Tuesday will file lawsuits against two companies that the drug giant is accusing of mass compounding ...

LillyDirect will help provide services to millions of patients who have yet to be formally diagnosed with the disease.

Lilly has already sued more than two dozen medical spas, wellness centers and compounding pharmacies for selling products ...

Eli Lilly (NYSE:LLY) experienced a 6% increase in price over the last quarter, coinciding with several major developments.

Eli Lilly And Co (NYSE:LLY), on Sunday, announced positive Phase 2 results for lepodisiran, an investigational small ...

Eli Lilly & Co. is targeting additional drug compounders and telehealth companies that make copycat versions of its weight ...

After a previously reported positive phase 2 trial in systemic lupus erythematosus (SLE), the TYK2 inhibitor deucravacitinib ...

GlobalData’s Emerging Market Outsourcing report reveals that this push for domestic production could lead to increased ...

Eli Lilly's Alzheimer's treatment is approved for use in the U.S. but the European Medicines Agency recommended against the ...

LONDON/NEW YORK (Reuters) -Drugmakers are lobbying U.S. President Donald Trump to phase in tariffs on imported pharmaceutical ...